BRCA Biomarkers
Investigational Cancer Drug Deemed Highly Mutagenic in Cell Line Sequencing Study
Using whole-genome sequencing on drug-exposed cell lines, researchers saw high mutation rates in control cell lines intermittently treated with a compound called CX-5461.
Yemaachi Furthers African Cancer Research Agenda With New Breast Cancer Mutation, Research Networks
Premium
The firm is preparing to expand a whole-exome sequencing pilot study, while pushing forward several other pan-African cancer research initiatives.
Icelandic Study Links Actionable Genetic Variants to Reduced Lifespan
Using sequence data for almost 58,000 Icelanders, Decode Genetics researchers showed that actionable genotypes were associated with earlier death.
Omitting pre- and post-test genetic counseling did not increase distress for participants in the MAGENTA trial compared to those who received more counseling.
FDA Clears 23andMe BRCA1/2 Consumer Health Risk Report for 41 Additional Variants
The 510(k) clearance will allow 23andMe to offer breast, ovarian, prostate, and pancreatic cancer risk assessments for a broader range of populations.